Strong Start to 2025
Solventum began fiscal year 2025 with a strong performance, showcasing 4.3% organic sales growth and adjusted earnings per share of $1.34, marking four consecutive quarters of positive growth.
MedSurg Segment Performance
The MedSurg business reported a very strong quarter, achieving 6% organic growth driven by positive business performance and favorable order timing.
Dental Solutions and New Product Launches
The Dental Solutions segment showed resilience with new product launches like Filtek Easy Match and Clarity Precision Grip Attachments, aiding in offsetting market challenges.
Health Information Systems Growth
The HIS segment saw a 3.9% increase in revenue, driven by strong customer retention in Revenue Cycle Management software solutions.
Purification & Filtration Segment Demand
The Purification & Filtration segment experienced robust demand for bioprocessing solutions, indicating strength in end markets.
Guidance Adjustment
Solventum raised its full-year organic sales growth guidance to 1.5% to 2.5%, reflecting strong business momentum.